Nivolumab

A genetically engineered, fully humanized immunoglobulin G4 monoclonal antibody that binds to the PD-1 RECEPTOR, activating an immune response to tumor cells. It is used as monotherapy or in combination with IPILIMUMAB for the treatment of advanced malignant MELANOMA. It is also used in the treatment of advanced or recurring NON-SMALL CELL LUNG CANCER; RENAL CELL CARCINOMA; and HODGKIN'S LYMPHOMA.

Also Known As:

Networked: 6114 relevant articles (863 outcomes, 1311 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Hodi, F Stephen: 45 articles (12/2022 - 04/2014)
2.	Ascierto, Paolo A: 43 articles (10/2022 - 12/2014)
3.	Larkin, James: 42 articles (10/2022 - 12/2014)
4.	McDermott, David F: 39 articles (01/2022 - 07/2013)
5.	Schadendorf, Dirk: 38 articles (10/2022 - 01/2015)
6.	Wolchok, Jedd D: 37 articles (10/2022 - 07/2013)
7.	Long, Georgina V: 36 articles (12/2022 - 01/2015)
8.	Fujimura, Taku: 32 articles (01/2022 - 01/2016)
9.	Kondo, Tsunenori: 31 articles (10/2022 - 07/2017)
10.	Choueiri, Toni K: 31 articles (07/2022 - 06/2015)

Related Diseases

1.	Neoplasms (Cancer) 06/26/2023 - "However, after nivolumab monotherapy was started, the tumor diminished remarkably, and the quality of life of the patient dramatically improved. " 02/01/2020 - "Subgroup analyses indicated that nivolumab was most cost-effective for patients who were 65 years of age or older ($85,171/QALY), followed by female patients ($85,273/QALY) and patients with tumor PD-L1 expression at least 1% ($90,309/QALY). " 12/01/2021 - "[A Case of Esophagogastric Junction Cancer Treated Successfully with Conversion Surgery after Complete Response to Nivolumab Treatment]." 09/01/2021 - "However, her general condition gradually improved and CT imaging 4 months after the first dose of nivolumab showed marked tumor shrinkage. " 01/01/2021 - "Nivolumab for Metastatic Urothelial Cancer in a Renal Allograft Recipient With Subsequent Graft Rejection and Treatment Complete Remission: A Case Report."
2.	Melanoma (Melanoma, Malignant) 11/01/2023 - "Nivolumab is an anti-PD1 antibody that has dramatically improved metastatic melanoma patients' outcomes. " 07/14/2021 - "Complete remission in metastatic primary malignant melanoma of the esophagus with nivolumab: a case report." 01/01/2018 - "Rapid complete remission of metastatic melanoma after first-line treatment with nivolumab plus tumor-infiltrating lymphocytes." 10/25/2023 - "The combination of nivolumab + relatlimab is superior to nivolumab alone in the treatment of naive patients and has activity in PD-1 refractory melanoma. " 01/01/2022 - "After 4 years' minimum follow-up, the AJCC-7 superior efficacy of nivolumab over ipilimumab in patients with resected stage III melanoma was preserved per AJCC-8 analysis. "
3.	Renal Cell Carcinoma (Grawitz Tumor) 01/01/2018 - "Nivolumab, an anti-programmed cell death protein-1 antibody, has been proven effective and safe in treating metastatic renal cell carcinoma (RCC) with a clear cell component. " 01/01/2017 - "Successful Therapy with Nivolumab in Metastatic Renal Cell Carcinoma After Multiple Prior Treatments." 03/01/2018 - "Nivolumab, an anti-PD1 immune control point inhibitor, is the first treatment that has improved the overall survival of patients after first-line metastatic renal cell carcinoma in 2015. " 05/01/2021 - "Nivolumab may be a promising treatment option for non-clear cell renal cell carcinoma such as papillary renal cell carcinoma." 01/01/2022 - "The phase II NIVOREN GETUG-AFU 26 study reported safety and efficacy of nivolumab in patients with metastatic clear cell renal cell carcinoma (m-ccRCC) in a 'real-world setting'. "
4.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/01/2018 - "Nivolumab for the treatment of advanced nonsmall cell lung cancer (NSCLC) evaluated in phase III trials showed 50% progression at first evaluation, but better overall survival (OS), suggesting regained efficacy of treatments given thereafter. " 01/01/2016 - "So far, a number of clinical trials on nivolumab have showed satisfactory efficacy in treating non-small-cell lung cancer (NSCLC). " 05/01/2020 - "Nivolumab is effective in previously treated patients with metastatic non-small cell lung cancer. " 11/23/2018 - "For non-small cell lung cancer (NSCLC), nivolumab was not cost-effective for a general cohort, but increased PD-L1 cutoffs resulted in CE. " 01/01/2018 - "Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity."
5.	Squamous Cell Carcinoma of Head and Neck 09/26/2018 - "The CheckMate 141 randomized phase 3 trial proved the efficacy of nivolumab in the treatment of R/M HNSCC as it was shown to significantly increase overall survival and quality of life. " 05/17/2017 - "Indeed, in a recent phase 3 study, the PD1 inhibitor nivolumab has recently demonstrated a significant improvement in overall survival for platin-resistant recurrent and/or metastatic HNSCC. " 12/01/2020 - "The development of irAEs is a strong predictor of improved survival in patients with advanced HNSCC treated with nivolumab." 09/01/2019 - "Nivolumab appear to have a clear clinical benefit for R/M-HNSCC, based on improved survival, good toxicity profile, reduction in symptoms and improvement in overall quality of life. " 02/01/2020 - "Although nivolumab treatment is effective in extending the overall survival (OS) in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC), only a few patients benefit from this treatment. "

Related Drugs and Biologics

1.	Ipilimumab
2.	pembrolizumab
3.	Immune Checkpoint Inhibitors
4.	Sunitinib (Sutent)
5.	Platinum
6.	cabozantinib
7.	Antibodies
8.	atezolizumab
9.	Monoclonal Antibodies
10.	Biomarkers (Surrogate Marker)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Immunotherapy
4.	Radiotherapy
5.	Neoadjuvant Therapy